Abstract: A method for controlling a charging apparatus of a vehicle, in particular an electric or hybrid vehicle, wherein the charging apparatus has a charging device including a protection and monitoring device. The vehicle includes a high-voltage on-board power system and an electrical energy storage apparatus connected to the high-voltage on-board power system. The method includes electrically connecting the high-voltage on-board power system to charging connections of an energy supply system by the charging apparatus. The charging connections include a neutral conductor, a protective conductor and at least one phase conductor. A protective conductor resistance is detected between the neutral conductor and the protective conductor by feeding in a test current by the protection and monitoring device. A frequency of the test current is filtered out of the compensation frequency range on a narrowband basis.

Abstract: The present invention generally relates to T-cells, such as CD8+ T-cells, CD4+ T-cells, CD3+ T-cells, ?? T-cells or natural killer (NK) T-cells, transfected/transduced with a fusion protein which is recruited by the use of trivalent, bispecific antibody molecule which specifically binds to/interacts with the extracellular domain of the fusion protein. More precisely, the present invention relates to a kit comprising the nucleic acid molecules, vectors and/or the fusion proteins of the present invention and the trivalent, bispecific antibody molecules of the present invention. Further aspects of the inventions are expression vectors comprising nucleic acid molecules encoding the fusion proteins as well as the trivalent, bispecific antibody molecules. Further, a process for the production of the trivalent, bispecific antibody molecules of the invention and a medicament/pharmaceutical composition comprising said trivalent, bispecific antibody molecules are described.

Abstract: The present invention relates to PD-1-CD28 fusion proteins, nucleic acid molecules, vectors, transduced cells carrying nucleic acid molecules or vectors of the present invention or expressing the fusion proteins of the present invention, methods and kits comprising the nucleic acid molecules, vectors and/or the fusion proteins of the present invention. The invention also provides the use of said transduced cells in a method for the treatment of particular diseases as well as a pharmaceutical composition/medicament comprising said transduced cells expressing the fusion proteins of the present invention for use in a method of treating of diseases, in particular in the medical intervention of diseases characterized by PD-L1 and/or PD-L2 expression.

Abstract: The present invention relates to CXCR6-transduced (a) T cell(s) such as (a) CD8+ T cell(s), (a) CD4+ T cell(s), (a) CD3+ T cell(s), (a) ?? T cell(s) or (a) natural killer (NK) T cell(s) for targeted tumor therapy, nucleic acid sequences, vectors capable of transducing such (a) T cell(s), (a) transduced T cell(s) carrying the nucleic acid sequences or vectors of the present invention, methods and kits comprising the nucleic acid sequences or vectors of the present invention. The invention also provides the use of said transduced T cell(s) in a method for the treatment of diseases characterized by CXCL16 overexpression as well as a pharmaceutical composition/medicament comprising (a) transduced T cell(s) expressing the CXCR6 for use in methods of treating diseases characterized by CXCL16 overexpression.

Abstract: A circuit includes an active element, a drive circuit for the active element and a control logic for providing a control signal for the drive circuit. Further, an interface circuit is provided, which includes a primary terminal for receiving a primary signal and a secondary terminal that is galvanically isolated from the primary terminal. The interface circuit is implemented to provide the primary signal received at the primary terminal to the control logic via the secondary terminal, and to provide, based on the primary signal received at the primary terminal, by means of a rectifier circuit, an auxiliary energy signal for the drive circuit at the secondary terminal.

Abstract: A circuit includes an active element, a drive circuit for the active element and a control logic for providing a control signal for the drive circuit. Further, an interface circuit is provided, which includes a primary terminal for receiving a primary signal and a secondary terminal that is galvanically isolated from the primary terminal. The interface circuit is implemented to provide the primary signal received at the primary terminal to the control logic via the secondary terminal, and to provide, based on the primary signal received at the primary terminal, by means of a rectifier circuit, an auxiliary energy signal for the drive circuit at the secondary terminal.

Abstract: The present invention relates to a bispecific (monoclonal) antibody molecule with a first binding domain binding an antigen on CD8+ T-cells that does not naturally occur in and/or on CD8+ T-cells and a second binding domain binding to a tumor specific antigen naturally occurring on the surface of a tumor cell. The bispecific (monoclonal) antibody molecules are particularly useful in combination with transduced CD8+ T-cells comprising an antigen which does not naturally occur in and/or on CD8+ T-cells and/or a T-cell receptor.

Abstract: Tis invention provides oligonucleotide agents that modulate an immune response by stimulating IFN production and methods of using such agents for therapeutic treatments of mammals.

Abstract: This invention provides oligonucleotide agents that modulate an immune response by stimulating IFN production and methods of using such agents for therapeutic treatments of mammals.

Abstract: This invention provides oligonucleotide agents that modulate an immune response by stimulating IFN production and methods of using such agents for therapeutic treatments of mammals.

Abstract: The present invention relates to methods and compositions for the treatment of chronic infections or malignant diseases, particularly chronic, interferon-resistant viral infections such as hepatitis B infections. Further, the present invention relates to methods and compositions for the improvement of interferon-&agr; therapies.